With several biosimilars already on the market around the world – including in the US, Europe, Canada and Australia – Mylan is among the global leaders in this sector of the off-patent industry. However, the company’s chief commercial officer Tony Mauro says that Mylan’s existing biosimilars are merely the beginning for a business that is only just starting out on its long journey.
Speaking as the firm announced its first-quarter results for 2020, Mauro set out where the firm’s biosimilars business currently stood...
